Safety and efficacy study of retifanlimab and epacadostat in combination with radiation and bevacizumab in patients with recurrent glioblastoma.

被引：3
|
作者：
Campian, Jian Li
Abraham, Christopher
Luo, Jingqin
Talcott, Grayson
Katumba, Ruth
Kim, Albert H.
Dunn, Gavin P.
Ansstas, George
Johanns, Tanner Michael
Ciorba, Matthew A.
Chheda, Milan G.
Huang, Jiayi
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
[2] Washington Univ, St Louis, MO 63110 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS2070
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2070
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Efficacy and safety study of fotemustine and bevacizumab in patients with recurrent glioblastoma.
    Escudero, Laura Sanchez
    Urbano, Maria Amor
    Garces, Maria Yeray Rodriguez
    Murillo, Fatima Toscano
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Efficacy and safety of selinexor in recurrent glioblastoma.
    Lassman, Andrew B.
    Wen, Patrick Y.
    Van den Bent, Martin J.
    Plotkin, Scott Randall
    Walenkamp, Anna Maria Elisabeth
    Huang, Xiu
    Rodriguez-Lopez, Karla
    Kauffman, Michael G.
    Shacham, Sharon
    Mau-Sorensen, Morten
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Dose-dependent efficacy of bevacizumab in recurrent glioblastoma.
    Melhem, Jawad
    Tahir, Ali
    Calabrese, Eirena
    Granovskaya, Inga
    Atenafu, Eshetu G.
    Sahgal, Arjun
    Lim-Fat, Mary Jane
    Perry, James R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.
    Ghiaseddin, Ashley
    Reardon, David A.
    Massey, Woody
    Mannerino, Alexandra
    Lipp, Eric S.
    Herndon, James E.
    McSherry, Frances
    Desjardins, Annick
    Randazzo, Dina M.
    Vlahovic, Gordana
    Friedman, Henry S.
    Peters, Katherine B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] SAFETY AND EFFICACY OF BEVACIZUMAB AND ERLOTINIB FOR RECURRENT GLIOBLASTOMA PATIENTS IN A PHASE II STUDY
    Sathornsumetee, Sith
    Desjardins, Annick
    Vredenburgh, James
    Rich, Jeremy
    Gururangan, Sridharan
    Friedman, Allan
    Friedman, Henry
    Reardon, David
    [J]. NEURO-ONCOLOGY, 2008, 10 (05) : 827 - 827
  • [6] Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma.
    Bota, D. A.
    Eroglu, Z.
    Reardon, D. A.
    Fu, B. D.
    Norfleet, J.
    Desjardins, A.
    Linskey, M. E.
    Peters, K.
    Friedman, H. S.
    Vredenburgh, J. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] BEVACIZUMAB IN COMBINATION WITH IRINOTECAN OR TEMOZOLOMIDE IN RECURRENT GLIOBLASTOMA: EFFICACY AND SAFETY RESULTS FROM A PILOT STUDY
    Kobyakov, Grigory
    Absalyamova, O.
    Amanov, R.
    [J]. NEURO-ONCOLOGY, 2010, 12 : 54 - 54
  • [8] Profiling response to carmustine/bevacizumab in recurrent glioblastoma.
    Rojas, Leonardo
    Cardona, Andres F.
    Wills, Beatriz
    Arrieta, Oscar
    Vargas, Carlos A.
    Carranza, Hernan
    Otero, Jorge M.
    Useche, Nicolas
    Bermudez, Sonia
    Jimenez, Enrique
    Hakim, Fernando
    Balana, Carmen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM).
    Reardon, David A.
    De Groot, John Frederick
    Colman, Howard
    Jordan, Justin T.
    Daras, Mariza
    Clarke, Jennifer Leigh
    Nghiemphu, Phioanh Leia
    Gaffey, Sarah C.
    Peters, Katherine B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Safety and efficacy of bevacizumab biosimilar in recurrent/progressive glioblastoma
    Kumar, Gunjesh
    DSouza, Hollis
    Menon, Nandini
    Srinivas, Sujay
    Vallathol, Dilip Harindran
    Boppana, Mounika
    Rajpurohit, Annu
    Mahajan, Abhishek
    Janu, Amit
    Chatterjee, Abhishek
    Krishnatry, Rahul
    Gupta, Tejpal
    Jalali, Rakesh
    Patil, Vijay M.
    [J]. ECANCERMEDICALSCIENCE, 2021, 15
12345